BPC-157: what the evidence actually says (and what it doesn't)

People drop the study count on BPC-157 like it ends the argument. Hundreds of papers. Must mean something.

Here’s what they leave out: the literature is overwhelmingly rodent. A 2025 Pharmaceuticals literature and patent review by Józwiak et al. surveys the full picture, and the human file is thin enough to count. That’s not a gotcha — the animal data is real and genuinely interesting. But if you’re about to inject this, repairs-a-rat-tendon and repairs-yours are different sentences. The gap between them is the whole story. Most of the internet skips it.

What it is, and why the animal data looks so good

BPC-157 is a peptide — fifteen amino acids — a fragment of a larger protein called body protection compound. A lab in Zagreb run by a researcher named Sikirić has been studying it since the early 1990s.

What gets people excited is the range. Most compounds do one thing in one tissue. BPC-157 seems to help repair across the board — tendons, muscle, ligament, bone, the gut lining, even nerve tissue. A 2025 narrative review on musculoskeletal healing catalogues the repair signal across tissue types. A 2025 systematic review in orthopaedic sports medicine by Vasireddi and colleagues describes it as an emerging candidate for tendon, ligament, and bone damage, drawing from preclinical and early clinical work.

That kind of consistency isn’t random. Something is genuinely happening here in the animal models. The question is whether it survives the trip out of a rodent and into a person.

One thing to hold onto, though. Nearly all of those hundreds of papers come from the same lab. Sikirić’s group, three decades, most of the literature. That doesn’t make the work wrong — some compounds are niche enough that one team does most of the digging. But a result checked mostly by the people most invested in it hasn’t had the outside scrutiny you’d want before you trust it with your own body.

Why it might actually work — and the catch

The interesting bit is the mechanism. BPC-157 appears to grow new blood vessels. It switches on signalling that your body uses to build fresh plumbing into damaged tissue. More blood supply means more oxygen and more repair crew reaching the injury. That’s the likely explanation for why the rat tendons bounce back, and why the effect generalises across so many tissue types.

Here’s the catch, and it’s a real one. Tumours need blood vessels too. Growing a blood supply is exactly how a harmless cluster of cells becomes dangerous. There’s a whole class of cancer drugs designed to block the pathway this peptide activates.

So the question writes itself. If something is quietly growing in you that you don’t know about, and you start using a compound that promotes the exact thing tumours need — what happens?

Nobody knows. Genuinely. A 2025 literature review by Józwiak et al. in the journal Pharmaceuticals became the flashpoint: its account of BPC-157’s angiogenic and proliferative mechanisms raised whether those same properties could, in principle, feed tumour growth. Sikirić’s group answered in the same journal — a 2025 comment by Sikirić et al. cites decades of animal work with no tumour induction and a consistently cytoprotective profile — defending the angiogenesis and nitric-oxide mechanisms as protective rather than dangerous.

Both positions are defensible. That’s not me dodging — it’s where the science actually sits. An argument in print, with no human evidence to settle it.

Does BPC-157 cause cancer? Nobody knows yet. No study has confirmed it. No study has ruled it out.

From rat to human is further than it sounds

Here’s the part the forums skip entirely.

BPC-157 came from stomach juice, and one thing it’s genuinely good at is surviving in there. Your stomach is full of enzymes that shred most peptides in minutes. This one shrugs them off. That’s unusual, and it’s why people think you can take it as a pill.

But surviving your stomach is step one of about five. Surviving the acid doesn’t mean it crosses from your gut into your blood. Getting into your blood doesn’t mean it reaches a torn tendon in your shoulder. And reaching it doesn’t mean it shows up in a high enough dose to do anything. Each of those is a separate question, and for humans, we have answers to none of them.

That’s not a figure of speech. There was supposed to be data. A Phase I trial registered in 2015 as PCO-02, brand name Bepecin, NCT02637284, planned for 42 healthy volunteers — designed to nail the basics: where the compound goes, how long it lasts, what a real dose looks like. The ClinicalTrials.gov record then went quiet. Status: Unknown. No results posted. It’s not even clear whether anyone enrolled.

That gap is still open — which means every microgram figure traded in forums is scaled up from rodents, not measured in people.

The human evidence, in full

This is the shortest section, because the answer is short.

Two human reports exist, and both sit outside injury. A 2025 safety pilot by Lee and Burgess gave intravenous BPC-157 to two volunteers over three days and recorded no adverse effects — uncontrolled, no efficacy measured, no injury involved, two people. A 2024 open-label pilot by Lee and colleagues gave a single bladder-wall injection to twelve women with interstitial cystitis; all twelve reported feeling better on questionnaires — uncontrolled, subjective, and nothing to do with a tendon.

Both are also small, uncontrolled, and ran in a low-tier journal. Worth saying plainly rather than burying.

For comparison: a normal drug clears three stages before anyone takes it seriously — safety in healthy people, then early dosing in patients, then proper randomised trials. BPC-157 hasn’t cleared stage one cleanly. In human terms it’s standing at the trailhead. Not halfway up the mountain — the trailhead.

What shifts the picture — a little, and only as of 2026 — is the first controlled trial that actually targets an injury. A Phase 2 randomised, placebo-controlled study of BPC-157 for acute hamstring strain (NCT07437547) is now recruiting. No results yet. But for the first time the question is being asked the right way, in roughly the population that’s been self-experimenting for years. One recruiting trial is not an answer. It’s the difference between a question nobody was testing and one somebody finally is.

The flood of testimonials is a different thing. It’s huge, it’s enthusiastic, and it’s been building for years — people reporting tendons that finally healed, joints that stopped aching, guts that settled. That’s real in the sense that real people are really saying it. It just isn’t evidence in the sense that lets you know what caused it, rule out the placebo effect, or work out who gets hurt. The stories tell you what to ask. They don’t tell you the answer.

Is the safety record actually reassuring?

Three decades of rat studies, no tumours. That counts for something — if there were a screaming cancer signal, we’d probably have seen it by now.

But no-flag-in-rats and safe-in-you are different claims, for three plain reasons.

One: it’s mostly one lab again. A safety record built largely by the discoverers isn’t an independent safety record.

Two: rats don’t live long. Three decades of studies is a lot of animals but not much time — a few rodent lifetimes, not the decades a 45-year-old might be on this stuff. Anything that takes twenty years to show up in a human will never show up in a mouse.

Three: that cancer question from earlier still isn’t resolved. The argument ran in a peer-reviewed journal in 2025 and ended in a draw. Both possibilities are still live.

The honest read: no signal in animals is mild reassurance, and better than the alternative. It’s not reassurance about you. That data hasn’t been collected.

What would actually settle this

If BPC-157 were going to earn the confidence people already give it, here’s what it’d take.

First, the basic human numbers — where it goes, how long it lasts, how a pill compares to an injection. The exact data the 2015-registered PCO-02 trial was built to produce and still hasn’t.

Second, other labs reproducing the results. Not because Sikirić’s group did anything suspect — their work is consistent and well-documented. But one lab finding something for thirty years needs outside eyes before you bet your body on it.

Third, real trials — people, placebo, proper design — not testimonials and not open-label pilots. That part has, at last, started: the hamstring strain trial now recruiting is the first of exactly this kind.

Fourth, a straight answer on the cancer question, tested in people rather than argued from rats.

Some of that scrutiny is, for once, actually scheduled. The FDA put BPC-157 on its Section 503A bulk drug substances docket — Federal Register notice 2026-07361 — for review by the Pharmacy Compounding Advisory Committee on July 23, 2026. The reviewed indication is ulcerative colitis. Not tendons. That mismatch is its own data point: the indication the regulator is sizing this peptide up for is one almost none of its current users are taking it for. Whatever the committee lands on, it’ll be the first time this compound’s evidence gets picked apart by people with nothing riding on the outcome.

Hold all three of these at once: the mechanism is plausible, the animal data is consistent, and the controlled human evidence is a single injury trial that started recruiting this year and has reported nothing yet. None of those cancels the others out. That’s just where BPC-157 sits today.

Which is exactly why, if you’ve been buying it off a website that ships in a Mylar bag, a lot of people — once they’ve read this far — decide the smarter move is to wait for the version where a real pharmacy makes it, a real physician signs off, and you actually know what’s in the vial and at what dose.

That’s what we’re building. Wolverine Health is a physician-supervised peptide service — real prescriptions, US-licensed compounding pharmacies, every batch third-party tested. It isn’t live yet, because the regulation isn’t either, and we’re not going to sell you ahead of the science. If you want to know the moment legitimate BPC-157 is actually available — with the same honesty you just read, including the parts that don’t flatter us — join the waitlist.